Navigation Links
Hospira Reports First-Quarter 2012 Results
Date:5/1/2012

for full-year 2012, projecting a net sales change in a range of negative 1 percent to positive 2 percent on a constant-currency basis, with foreign exchange expected to detract from results by a negative 1 percent.

Adjusted* diluted earnings per share projections for full-year 2012 remain in a range of $2.00 to $2.30.

The reconciliation between the projected 2012 adjusted* diluted earnings per share and GAAP diluted earnings per share follows:

Diluted earnings per share -- adjusted*

$2.00 - $2.30Estimated amortization of intangible assets
related to certain acquisitions (mid-point of an
estimated range of $0.28 to $0.32 per diluted share)($0.30)Estimated charges for certain quality and
product-related matters (mid-point of an
estimated range of $0.50 to $0.62 per diluted share)

($0.56)Estimated charges related to capacity expansion
(mid-point of an estimated range of $0.09 to $0.11
per diluted share)

($0.10)Diluted earnings per share -- GAAP

$1.04 - $1.34The adjusting items are shown net of tax in aggregate of $86 million, which is calculated for the specified adjustments stated above, based on the statutory tax rates in the various tax jurisdictions in which the items are expected to occur.

The company continues to project that cash flow from operations in 2012 will be between $575 million and $625 million. Depreciation and amortization is expected to be between $240 million and $260 million, and capital expenditures are projected to range between $350 million and $400 million.

*Use of Non-GAAP Financial MeasuresAdjusted measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K furnished t
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Joins the Generic Pharmaceutical Association
3. Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Months Supply of New Product Immediately and on Track to Ensure Sustainable Supply
4. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
5. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
6. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
7. Hospira Reports Third-Quarter 2011 Results
8. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
9. Hospira to Host Conference Call for Third-Quarter 2011 Results
10. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
11. Hospira to Host 2011 Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare certified agencies ... Texas, New Mexico, New Jersey, Virginia, and Puerto Rico, was ... of PAM’s 2014 Gala. , North Texas PAMS is ... Texas chapter was created by a handful of Peruvian physicians ... care for the indigent in Peru. The chapter is developing ...
(Date:7/27/2014)... July 28, 2014 Recently, Wdsshop.de, a reliable ... new collection of fabulous prom dresses on its ... discounted prices, up to 58% off. , “We are pleased ... product line. They are specially created for those who are ... is great and vivid in style. I think our clients ...
(Date:7/27/2014)... provide shorter, more effective treatment options with fewer side ... C, even those most difficult to treat, according to ... Lancet . , Both studies focused on hepatitis C ... the USA, Europe, North Asia, Australia, and South America, ... Around 150 million people worldwide have chronic hepatitis C ...
(Date:7/27/2014)... Ticket Down is a reputable source ... in Inglewood, California on November 15th. This Australian boy band ... to hear songs from this amazing album at the concert. ... California at The Forum will be released for sale to the ... local time TicketDown.com. This popular secondary ticket exchange can also ...
(Date:7/27/2014)... Washington, DC (PRWEB) July 27, 2014 ... off as Latinos demonstrate their passion for protecting our ... community, particularly in the Southwest, will go on hiking ... presentations designed to show their support for permanently protecting ... is about sharing the Latino community’s perspective on the ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3
... 12 As the exclusive official,breaking news service ... 19-22, PR Newswire is featuring profiles of the ... Company: Defibtech, LLC, Booth Number: 16D18-11, ... LLC is a leading innovator in the field ...
... ForHealth Technologies, IntelliFill i.v. robot to ... reduces errors and ... ForHealth Technologies,Inc., a pioneer in medication error reduction and ... its robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the ...
... BERGEN, N.J., Nov. 12 The Vitamin Shoppe,announced ... Vice President,General Counsel and Corporate Secretary. Mr. Sander ... capacity, Mr. Sander will be responsible for,Legal Affairs, ... "As the Nation,s fastest growing specialty retailer of ...
... First member satisfaction survey shows health improvements, disease ... among valued benefits of plan -, SAN ANTONIO, Nov. ... 91 percent of members of Care Improvement Plus feel,their health ... satisfaction of the plan,s statewide membership. Of those who,feel health ...
... in the November issue of the Springer journal ... has been cut to levels substantially below the cost ... and clinics around the country are likely to discontinue ... to the test and jeopardizing those at risk for ...
... Donostia hospital in representation of Bioef are taking part in ... a portable device that will revolutionise the manner of controlling ... time needed for their detection from the current 24 hours ... to an increase in the number of control points. This ...
Cached Medicine News:Health News:Defibtech, LLC Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:The Vitamin Shoppe Names James Sander Vice President, General Counsel and Corporate Secretary 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Osteoporosis care at risk in the United States 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... The Wound Care Manager ... for patient assessment and data ... care. This application was developed ... Wound Care along with the ...
... specifically for the Palm Organizers to ... rounds. It is intended to record ... that are requested by the senior ... round examinations and to record the ...
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Medicine Products: